Krasaelap Amornluck, Madani Shailender
Pediatr Ann. 2017 Mar 1;46(3):e120-e125. doi: 10.3928/19382359-20170213-01.
Functional gastrointestinal disorders (FGIDs) negatively affect children's quality of life and health care costs. It has been proposed that alteration of gut serotonin leads to gastrointestinal dysmotility, visceral hypersensitivity, altered gastrointestinal secretions, and brain-gut dysfunction. Cyproheptadine, a serotonin antagonist, has been shown to be a potentially effective and safe treatment option in children who meet the clinical criteria for FGIDs. Well-designed multicenter trials with long-term follow-up are needed to further investigate its efficacy. [Pediatr Ann. 2017;46(3):e120-e125.].
功能性胃肠病（FGIDs）对儿童的生活质量和医疗费用产生负面影响。有人提出，肠道血清素的改变会导致胃肠动力障碍、内脏高敏感性、胃肠分泌物改变以及脑肠功能障碍。赛庚啶作为一种血清素拮抗剂，已被证明对于符合FGIDs临床标准的儿童是一种潜在有效且安全的治疗选择。需要设计良好的多中心试验并进行长期随访，以进一步研究其疗效。[《儿科年鉴》。2017年；46(3):e120 - e125。]
